Curis (CRIS) : Telemetry Investments L.l.c. reduced its stake in Curis by 20.63% during the most recent quarter end. The investment management company now holds a total of 250,000 shares of Curis which is valued at $925,000 after selling 65,000 shares in Curis , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Curis makes up approximately 1.53% of Telemetry Investments L.l.c.’s portfolio.
Other Hedge Funds, Including , Fmr boosted its stake in CRIS in the latest quarter, The investment management firm added 921,048 additional shares and now holds a total of 16,840,418 shares of Curis which is valued at $62,309,547. Curis makes up approx 0.01% of Fmr’s portfolio.Blackrock Fund Advisors boosted its stake in CRIS in the latest quarter, The investment management firm added 254,404 additional shares and now holds a total of 4,840,136 shares of Curis which is valued at $12,971,564.California Public Employees Retirement System reduced its stake in CRIS by selling 15,000 shares or 6.4% in the most recent quarter. The Hedge Fund company now holds 219,400 shares of CRIS which is valued at $603,350.
Curis closed down -0.11 points or -3.20% at $3.33 with 8,20,140 shares getting traded on Monday. Post opening the session at $3.46, the shares hit an intraday low of $3.31 and an intraday high of $3.53 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Curis reported $-0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.11 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.10. The company had revenue of $1.76 million for the quarter, compared to analysts expectations of $1.85 million. The company’s revenue was down -14.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.04 EPS.
Curis Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Company’s drug candidate CUDC-907 is an orally available small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis’ product pipeline also includes CUDC-427 an orally available small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma and human epidermal growth factor receptor 2 (HER 2-) estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Company’s PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.